Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Peerlinck

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
International Angiology : a Journal of the International Union of Angiology|May 29, 2012
Catheter-directed thrombolysis with microplasmin for acute peripheral arterial occlusion (PAO): an exploratory studyP Verhamme, S Heye, K Peerlinck, et al.
Thrombosis and Haemostasis|July 1, 1994
High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII productsE Briët, F R Rosendaal, W Kreuz, et al.
Thrombosis and Haemostasis|August 24, 1999
Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexesJ G Gilles, R Lavend'homme, K Peerlinck, et al.
Thrombosis and Haemostasis|May 6, 1998
Anti-hepatitis G E2 antibody detection and its relation to serum HGV-RNA in patients with clotting disorders: high prevalence of HGV infection and spontaneous remissionL Sheng, A Soumillion, K Peerlinck, et al.
Clinical Pharmacology and Therapeutics|October 1, 1994
Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy menJ S Barrett, G Murphy, K Peerlinck, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2015
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disordersM Jacquemin, J Toelen, J Schoeters, et al.
Blood|March 26, 1999
Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia AK Peerlinck, M G Jacquemin, J Arnout, et al.
Blood|December 23, 1999
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factorM Jacquemin, A Benhida, K Peerlinck, et al.
Blood|July 10, 1998
Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitorM G Jacquemin, B G Desqueper, A Benhida, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 18, 1998
Experiences with continuous infusion of recombinant activated factor VIIS Schulman, R d'Oiron, U Martinowitz, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
International Angiology : a Journal of the International Union of Angiology|May 29, 2012
Catheter-directed thrombolysis with microplasmin for acute peripheral arterial occlusion (PAO): an exploratory studyP Verhamme, S Heye, K Peerlinck, et al.
Thrombosis and Haemostasis|July 1, 1994
High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII productsE Briët, F R Rosendaal, W Kreuz, et al.
Thrombosis and Haemostasis|August 24, 1999
Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexesJ G Gilles, R Lavend'homme, K Peerlinck, et al.
Thrombosis and Haemostasis|May 6, 1998
Anti-hepatitis G E2 antibody detection and its relation to serum HGV-RNA in patients with clotting disorders: high prevalence of HGV infection and spontaneous remissionL Sheng, A Soumillion, K Peerlinck, et al.
Clinical Pharmacology and Therapeutics|October 1, 1994
Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy menJ S Barrett, G Murphy, K Peerlinck, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2015
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disordersM Jacquemin, J Toelen, J Schoeters, et al.
Blood|March 26, 1999
Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia AK Peerlinck, M G Jacquemin, J Arnout, et al.
Blood|December 23, 1999
A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factorM Jacquemin, A Benhida, K Peerlinck, et al.
Blood|July 10, 1998
Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitorM G Jacquemin, B G Desqueper, A Benhida, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|November 18, 1998
Experiences with continuous infusion of recombinant activated factor VIIS Schulman, R d'Oiron, U Martinowitz, et al.
Pageof 9